# Technology-Assisted Cholesterol Trial in Consumers (TACTiC)

Study · id `cardio:ct-nct04964544` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04964544](<https://clinicaltrials.gov/study/NCT04964544>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04964544

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1196 participants.

## Technical summary

Registry record NCT04964544. Allocation not applicable; no masking; primary purpose treatment. Start 2021-07-08 (actual); primary completion 2023-03-01 (actual). Results posted on 2024-10-30.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1196 participants (enrolled count; ClinicalTrials.gov record NCT04964544, source copy `cardio:ctgov-nct04964544-2024-10-30`, retrieved 2026-10-31)
- Started: 2021-07-08 (actual) (ClinicalTrials.gov record NCT04964544, source copy `cardio:ctgov-nct04964544-2024-10-30`, retrieved 2026-10-31)
- Primary completion: 2023-03-01 (actual) (ClinicalTrials.gov record NCT04964544, source copy `cardio:ctgov-nct04964544-2024-10-30`, retrieved 2026-10-31)
- Completion: 2023-03-01 (actual) (ClinicalTrials.gov record NCT04964544, source copy `cardio:ctgov-nct04964544-2024-10-30`, retrieved 2026-10-31)
- Results first posted: 2024-10-30 (ClinicalTrials.gov record NCT04964544, source copy `cardio:ctgov-nct04964544-2024-10-30`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04964544, source copy `cardio:ctgov-nct04964544-2024-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04964544-2024-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Technology-Assisted Cholesterol Trial in Consumers (TACTiC)
- Acronym: TACTiC
- Condition: High Cholesterol
- Intervention (Combination product): 5 mg rosuvastatin calcium with a Web App (combination product)
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Concentrics Research
- Collaborator class: OTHER
- Collaborator: Idea Evolver
- Collaborator class: INDUSTRY
- Collaborator: The Cleveland Clinic
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: The Cleveland Clinic (`cardio:org-the-cleveland-clinic`)

## Provenance

Content hash: 5d4582421fab075176cc26118d812e283b552ddf5fa27f25e7c01dfd5bb71495
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
